Aktis Oncology Expands Clinical Enrollment for Actinium-Based Radiopharmaceuticals
Recently, Aktis Oncology of the United States disclosed the latest expanded enrollment arrangements for two clinical studies of innovative targeted radiopharmaceuticals based on Actinium-225. While continuing to advance the established dose-escalation trials, the company has added dedicated supplementary enrollment cohorts at selected dose levels for AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, respectively, aiming to comprehensively observe the safety, tolerability, and preliminary antitumor activity of the drugs in specific patient populations, and to accumulate detailed data for subsequent large-scale clinical development. In terms of specific clinical progress, the Nectin-4-targeting AKY-...
2026-11-16